Local Drug Delivery via a Coronary Stent With Programmable Release Pharmacokinetics

Background—Fixed drug release kinetics and vessel wall partitioning may limit the effectiveness of drug-eluting stents. We report preliminary experience using a new coronary stent with programmable pharmacokinetics. Methods and Results—A newly designed metallic stent contains honeycombed strut elements with inlaid stacked layers of drug and polymer. In vitro studies evaluated recipes for loading paclitaxel to establish the parameters for controlling drug release. Manipulation of the layers of biodegradable polymer and drug allowed varying of the initial 24-hour burst release of paclitaxel from 69% to 8.6% (P <0.0001). Late release of drug could be adjusted dependently or independently of early burst release. A biphasic release profile was created by the addition of blank layers of polymer within the stack. In the 30-day porcine coronary model (n=17 pigs), there was a 70% reduction in late loss (0.3±0.5 versus 1.0±0.5 mm, P =0.04), a 28% increase in luminal volume (132±12 versus 103±21 mm3, P =0.02), and a 50% decrease in histological neointimal area (2.0±0.5 versus 4.0±1.6 mm2;P <0.001) compared with bare metal controls. Temporal and regional variations in vascular healing were seen histologically. Conclusions—Layered polymer/drug inlay stent technology permits flexible and controllable pharmacokinetic profiles. Programmable, complex chemotherapy using this approach may be feasible for the treatment of cardiovascular disease.

[1]  C. Di Mario,et al.  First Clinical Experience With a Paclitaxel Derivate–Eluting Polymer Stent System Implantation for In-Stent Restenosis: Immediate and Long-Term Clinical and Angiographic Outcome , 2002, Circulation.

[2]  J. Tardif,et al.  Biocompatibility aspects of new stent technology. , 1998, Journal of the American College of Cardiology.

[3]  E. Edelman,et al.  Arterial paclitaxel distribution and deposition. , 2000, Circulation research.

[4]  R. Virmani,et al.  Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.

[5]  E. Edelman,et al.  Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. , 2000, Journal of the American College of Cardiology.

[6]  E. Edelman,et al.  Physiological Transport Forces Govern Drug Distribution for Stent-Based Delivery , 2001, Circulation.

[7]  R. Fox American Heart Association 2001 scientific sessions: late-breaking science-drug-eluting stents. , 2001, Circulation.

[8]  Ousa,et al.  A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .

[9]  P. Serruys,et al.  Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.

[10]  John Crank,et al.  The Mathematics Of Diffusion , 1956 .

[11]  J Hausleiter,et al.  Effects of &bgr;–-Emitting 188Re Balloon in Stented Porcine Coronary Arteries: An Angiographic, Intravascular Ultrasound, and Histomorphometric Study , 2000, Circulation.

[12]  B. Abella,et al.  Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis , 2001, Circulation.

[13]  R E Vlietstra,et al.  Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.